Veradermics Management
Management criteria checks 1/4
Veradermics' CEO is Reid Waldman, appointed in Dec 2022, has a tenure of 3.17 years. total yearly compensation is $8.46M, comprised of 5.3% salary and 94.7% bonuses, including company stock and options. directly owns 0.63% of the company’s shares, worth $9.04M. The average tenure of the management team and the board of directors is 1 years and 4.4 years respectively.
Key information
Reid Waldman
Chief executive officer
US$8.5m
Total compensation
| CEO salary percentage | 5.32% |
| CEO tenure | 3.2yrs |
| CEO ownership | 0.6% |
| Management average tenure | 1yr |
| Board average tenure | 4.4yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | -US$62m |
| Dec 31 2024 | US$812k | US$371k | -US$27m |
Compensation vs Market: Reid's total compensation ($USD8.46M) is above average for companies of similar size in the US market ($USD5.23M).
Compensation vs Earnings: Reid's compensation has increased whilst the company is unprofitable.
CEO
Reid Waldman (30 yo)
Dr. Reid Waldman, M.D., co-founder and Director of VeraDermics, Inc. since October 2019 and has been its Chief Executive Officer since December 2022 and was its Chief Operating Officer. Under his stewardsh...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 3.2yrs | US$8.46m | 0.63% $ 9.0m | |
| President | 5.5yrs | US$3.31m | 0.32% $ 4.5m | |
| CFO & Treasurer | 1yr | US$2.21m | 0% $ 0 | |
| Senior Director of Manufacturing Sciences & Technology | no data | no data | no data | |
| General Counsel & Secretary | less than a year | no data | no data | |
| VP of Project & Program Management of Business Technology and Chief of Staff | no data | no data | no data | |
| Chief Commercial & Strategy Officer | less than a year | no data | no data | |
| Controller | no data | no data | no data | |
| Manager of Clinical Trial Recruitment & Site Engagement | no data | no data | no data | |
| Vice President of Development & Scientific Operations | no data | no data | no data | |
| Vice President of Clinical Development & Regulatory Affairs | no data | no data | no data | |
| Director of CMC Project Management | no data | no data | no data |
Experienced Management: MANE's management team is not considered experienced ( 1 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 6.3yrs | US$8.46m | 0.63% $ 9.0m | |
| Independent Non-Employee Director | 4.4yrs | no data | no data | |
| Independent Non-Employee Director | 1.2yrs | no data | no data | |
| Independent Non-Employee Director | less than a year | no data | no data | |
| Independent Non-Employee Director | 4.4yrs | US$7.89k | 0.35% $ 5.0m | |
| Independent Non-Employee Director | less than a year | no data | no data | |
| Independent Non-Employee Director | 4.4yrs | no data | 0.0066% $ 94.4k |
Experienced Board: MANE's board of directors are considered experienced (4.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/09 10:53 |
| End of Day Share Price | 2026/02/06 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Veradermics, Incorporated is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.